Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

TaiGen, YiChang HEC create JV in the Greater China region

Executive Summary

TaiGen Biotechnology Co. Ltd. and YiChang HEC ChangJiang Pharmaceutical Co. Ltd. have created a Chinese joint venture to develop, manufacture, and commercialize direct-acting antiviral agents (DAAs) for treating chronic hepatitis C virus (HCV) in mainland China, Taiwan, Hong Kong, and Macau.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Joint Venture
    • R&D and Marketing (Licensing)

Related Companies